JP2017537921A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537921A5 JP2017537921A5 JP2017529349A JP2017529349A JP2017537921A5 JP 2017537921 A5 JP2017537921 A5 JP 2017537921A5 JP 2017529349 A JP2017529349 A JP 2017529349A JP 2017529349 A JP2017529349 A JP 2017529349A JP 2017537921 A5 JP2017537921 A5 JP 2017537921A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- composition
- amino acid
- patient
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 72
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 72
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 72
- 230000035772 mutation Effects 0.000 claims description 61
- 108010092408 Eosinophil Peroxidase Proteins 0.000 claims description 38
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 claims description 33
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 claims description 33
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 claims description 33
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 claims description 33
- 101000707567 Homo sapiens Splicing factor 3B subunit 1 Proteins 0.000 claims description 30
- 102100031711 Splicing factor 3B subunit 1 Human genes 0.000 claims description 30
- 239000000018 receptor agonist Substances 0.000 claims description 25
- 229940044601 receptor agonist Drugs 0.000 claims description 25
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 24
- 210000000601 blood cell Anatomy 0.000 claims description 17
- 210000001185 bone marrow Anatomy 0.000 claims description 10
- 210000003743 erythrocyte Anatomy 0.000 claims description 9
- 102000001554 Hemoglobins Human genes 0.000 claims description 8
- 108010054147 Hemoglobins Proteins 0.000 claims description 8
- 208000007502 anemia Diseases 0.000 claims description 8
- 210000002798 bone marrow cell Anatomy 0.000 claims description 8
- 206010065973 Iron Overload Diseases 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 230000001582 osteoblastic effect Effects 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000000440 neutrophil Anatomy 0.000 claims description 3
- 230000000925 erythroid effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 25
- 102100028471 Eosinophil peroxidase Human genes 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 1
- 208000031162 sideroblastic anemia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 203
- 150000001413 amino acids Chemical group 0.000 description 138
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 32
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 32
- 239000005557 antagonist Substances 0.000 description 26
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 229910052742 iron Inorganic materials 0.000 description 7
- 238000007792 addition Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 206010069754 Acquired gene mutation Diseases 0.000 description 5
- 101100095662 Homo sapiens SF3B1 gene Proteins 0.000 description 5
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 5
- 239000000488 activin Substances 0.000 description 5
- 230000001934 delay Effects 0.000 description 5
- 230000037439 somatic mutation Effects 0.000 description 5
- 108010059616 Activins Proteins 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 206010058314 Dysplasia Diseases 0.000 description 4
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 4
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 4
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 4
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102100026818 Inhibin beta E chain Human genes 0.000 description 4
- 206010033661 Pancytopenia Diseases 0.000 description 4
- 108010023082 activin A Proteins 0.000 description 4
- 208000024389 cytopenia Diseases 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000009120 supportive therapy Methods 0.000 description 4
- 101000587430 Homo sapiens Serine/arginine-rich splicing factor 2 Proteins 0.000 description 3
- 102100029666 Serine/arginine-rich splicing factor 2 Human genes 0.000 description 3
- 108010023079 activin B Proteins 0.000 description 3
- 208000015322 bone marrow disease Diseases 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 108091006084 receptor activators Proteins 0.000 description 3
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 101150110046 Dnmt3a gene Proteins 0.000 description 2
- 101000728236 Homo sapiens Polycomb group protein ASXL1 Proteins 0.000 description 2
- 101000658084 Homo sapiens U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2 Proteins 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 102100029799 Polycomb group protein ASXL1 Human genes 0.000 description 2
- 101150012475 TET2 gene Proteins 0.000 description 2
- 102100035036 U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2 Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 102000018511 hepcidin Human genes 0.000 description 2
- 108060003558 hepcidin Proteins 0.000 description 2
- 229940066919 hepcidin Drugs 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 125000003473 lipid group Chemical group 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 102220061390 rs369115472 Human genes 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000007648 Glutathione S-Transferase pi Human genes 0.000 description 1
- 108010007355 Glutathione S-Transferase pi Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 1
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 description 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 1
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 208000007541 Preleukemia Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- -1 alemtuzumab Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 229960001489 deferasirox Drugs 0.000 description 1
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 description 1
- 229960003266 deferiprone Drugs 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 108010002601 epoetin beta Proteins 0.000 description 1
- 229960004579 epoetin beta Drugs 0.000 description 1
- 108010067416 epoetin delta Proteins 0.000 description 1
- 229950002109 epoetin delta Drugs 0.000 description 1
- 108010090921 epoetin omega Proteins 0.000 description 1
- 229950008767 epoetin omega Drugs 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086977P | 2014-12-03 | 2014-12-03 | |
| US62/086,977 | 2014-12-03 | ||
| US201462088087P | 2014-12-05 | 2014-12-05 | |
| US62/088,087 | 2014-12-05 | ||
| US201562155395P | 2015-04-30 | 2015-04-30 | |
| US62/155,395 | 2015-04-30 | ||
| PCT/US2015/063835 WO2016090188A1 (en) | 2014-12-03 | 2015-12-03 | Methods for treating myelodysplastic syndromes and sideroblastic anemias |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020121986A Division JP2020169217A (ja) | 2014-12-03 | 2020-07-16 | 骨髄異形成症候群および鉄芽球性貧血を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537921A JP2017537921A (ja) | 2017-12-21 |
| JP2017537921A5 true JP2017537921A5 (OSRAM) | 2019-01-17 |
| JP6737786B2 JP6737786B2 (ja) | 2020-08-12 |
Family
ID=56092498
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529349A Active JP6737786B2 (ja) | 2014-12-03 | 2015-12-03 | 骨髄異形成症候群および鉄芽球性貧血を処置するための方法 |
| JP2020121986A Pending JP2020169217A (ja) | 2014-12-03 | 2020-07-16 | 骨髄異形成症候群および鉄芽球性貧血を処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020121986A Pending JP2020169217A (ja) | 2014-12-03 | 2020-07-16 | 骨髄異形成症候群および鉄芽球性貧血を処置するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10189882B2 (OSRAM) |
| EP (1) | EP3226887B1 (OSRAM) |
| JP (2) | JP6737786B2 (OSRAM) |
| KR (1) | KR102603899B1 (OSRAM) |
| CN (1) | CN107405383A (OSRAM) |
| AU (2) | AU2015358398B2 (OSRAM) |
| CA (1) | CA2969413C (OSRAM) |
| HK (1) | HK1247115A1 (OSRAM) |
| MA (1) | MA41119A (OSRAM) |
| TW (2) | TWI758237B (OSRAM) |
| WO (1) | WO2016090188A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| CN107135646B (zh) * | 2014-06-13 | 2022-03-15 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| CA2986432A1 (en) | 2015-05-20 | 2016-11-24 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| WO2017079591A2 (en) | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| US10550170B2 (en) | 2015-11-23 | 2020-02-04 | Acceleron Pharma Inc. | Methods for treating vascular eye disorders with actrii antagonists |
| JP7058606B2 (ja) * | 2016-02-22 | 2022-04-22 | アクセルロン ファーマ インコーポレイテッド | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
| AU2017302282B2 (en) | 2016-07-27 | 2024-07-25 | Acceleron Pharma Inc. | Methods and compositions for treating myelofibrosis |
| WO2018089706A2 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| WO2019094751A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
| CN108113965A (zh) * | 2018-01-25 | 2018-06-05 | 苏州科技城医院 | 一种氟碳化合物脂质体及其制备方法 |
| AU2019266314B2 (en) | 2018-05-09 | 2025-05-15 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| US20210346464A1 (en) * | 2018-10-31 | 2021-11-11 | Celgene Corporation | TREATMENT OF ANEMIA DUE TO VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS USING ACTIVIN-ACTRll LIGAND TRAPS |
| CN114761013A (zh) * | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| WO2021189010A1 (en) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| WO2021189006A1 (en) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
| US20230181690A1 (en) * | 2020-04-13 | 2023-06-15 | Celgene Corporation | Methods for treating anemia using an actriib ligand trap and fedratinib |
| CN113604562B (zh) * | 2020-05-05 | 2024-01-02 | 北京市神经外科研究所 | Sf3b1基因突变在泌乳素型垂体腺瘤辅助诊断中的应用 |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| EP4149441A4 (en) * | 2020-05-15 | 2024-03-13 | Celgene Corporation | METHODS AND COMPOSITIONS FOR TREATING ANEMIA WITH ACTRIIB LIGAND TRAP AND MTOR INHIBITORS |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| CA3205845A1 (en) * | 2021-01-20 | 2022-07-28 | Francesca VINCHI | Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds) |
| EP4359075A4 (en) * | 2021-06-21 | 2025-05-14 | Keros Therapeutics, Inc. | METHODS OF USING INHIBITORS OF ACTIVIN RECEPTOR TYPE II SIGNALING |
| AU2023234185A1 (en) | 2022-03-16 | 2024-10-03 | Daiichi Sankyo Company, Limited | siRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2 |
| WO2025015263A2 (en) * | 2023-07-13 | 2025-01-16 | Mayo Foundation For Medical Education And Research | Treating myeloid disorders |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5707796A (en) | 1990-06-11 | 1998-01-13 | Nexstar Pharmaceuticals, Inc. | Method for selecting nucleic acids on the basis of structure |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| NZ306767A (en) | 1995-04-11 | 2000-03-27 | Univ Johns Hopkins | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6699843B2 (en) | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
| US6011577A (en) | 1997-06-30 | 2000-01-04 | Polaroid Corporation | Modular optical print head assembly |
| WO1999010364A1 (en) | 1997-08-29 | 1999-03-04 | Human Genome Sciences, Inc. | Follistatin-3 |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| EP1141708A1 (en) | 1998-12-28 | 2001-10-10 | Sunesis Pharmaceuticals Inc. | Identifying small organic molecule ligands for binding |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ATE322681T1 (de) | 1999-01-21 | 2006-04-15 | Metamorphix Inc | Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen |
| DE60042021D1 (de) | 1999-07-29 | 2009-05-28 | Gilead Sciences Inc | Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors |
| CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| BR0315316A (pt) | 2002-10-15 | 2005-08-16 | Celgene Corp | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20070135336A1 (en) | 2003-09-15 | 2007-06-14 | De Kretser David | Follistatin isoforms and uses thereof |
| MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| ES2426005T3 (es) | 2004-07-23 | 2013-10-18 | Acceleron Pharma Inc. | Polipéptidos del receptor ACTRII, procedimientos y composiciones |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| WO2006052842A2 (en) | 2004-11-09 | 2006-05-18 | The Trustees Of The University Of Pennsylvania | Methods for diagnosis of myelodysplastic syndromes (mds) |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| EP3811965A1 (en) | 2005-11-23 | 2021-04-28 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| AR060871A1 (es) | 2006-05-09 | 2008-07-16 | Genentech Inc | Union de polipeptidos con supercontigos optimizados |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| UA116871C2 (uk) | 2006-12-18 | 2018-05-25 | Акселерон Фарма Інк. | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| EP2599495A1 (en) * | 2007-02-01 | 2013-06-05 | Acceleron Pharma, Inc. | Activin-ActRIIa Antagonists and Uses for Treating or Preventing Breast Cancer |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| CA2729096C (en) | 2008-06-26 | 2020-04-28 | Acceleron Pharma Inc. | Methods for dosing an actriib antagonist and monitoring of treated patients |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| HUE051137T2 (hu) | 2008-08-14 | 2021-03-01 | Acceleron Pharma Inc | GDF-csapdák |
| ES2844123T3 (es) * | 2009-08-13 | 2021-07-21 | Acceleron Pharma Inc | Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos |
| EP2412798A1 (en) | 2010-07-27 | 2012-02-01 | Gambro Lundia AB | Biomimetic membrane for cell expansion |
| CN107837390A (zh) * | 2011-10-17 | 2018-03-27 | 阿塞勒隆制药公司 | 用于治疗无效性红细胞生成的方法和组合物 |
| EP2911682A4 (en) * | 2012-10-24 | 2016-03-23 | Celgene Corp | METHOD FOR TREATING ANEMIA |
| KR102520970B1 (ko) | 2014-03-21 | 2023-04-12 | 악셀레론 파마 인코포레이티드 | 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법 |
| EP3808778A1 (en) | 2014-04-18 | 2021-04-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating sickle-cell disease |
| CN107135646B (zh) | 2014-06-13 | 2022-03-15 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| AU2016261913B2 (en) | 2015-05-13 | 2021-08-12 | Acceleron Pharma Inc. | Treatment of beta-thalassemia using ActRII ligand traps |
| EP3331550B1 (en) | 2015-08-04 | 2022-11-02 | Acceleron Pharma Inc. | Composition for treating myeloproliferative disorders |
-
2015
- 2015-12-02 MA MA041119A patent/MA41119A/fr unknown
- 2015-12-03 TW TW104140598A patent/TWI758237B/zh active
- 2015-12-03 KR KR1020177017082A patent/KR102603899B1/ko active Active
- 2015-12-03 JP JP2017529349A patent/JP6737786B2/ja active Active
- 2015-12-03 AU AU2015358398A patent/AU2015358398B2/en active Active
- 2015-12-03 WO PCT/US2015/063835 patent/WO2016090188A1/en not_active Ceased
- 2015-12-03 EP EP15865103.4A patent/EP3226887B1/en active Active
- 2015-12-03 HK HK18106801.6A patent/HK1247115A1/zh unknown
- 2015-12-03 CN CN201580075439.3A patent/CN107405383A/zh active Pending
- 2015-12-03 TW TW111105042A patent/TW202220689A/zh unknown
- 2015-12-03 CA CA2969413A patent/CA2969413C/en active Active
- 2015-12-03 US US14/958,551 patent/US10189882B2/en active Active
-
2018
- 2018-12-05 US US16/210,525 patent/US10829531B2/en active Active
-
2020
- 2020-07-16 JP JP2020121986A patent/JP2020169217A/ja active Pending
- 2020-10-01 US US17/060,989 patent/US20210230239A1/en not_active Abandoned
-
2021
- 2021-12-23 AU AU2021290319A patent/AU2021290319A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537921A5 (OSRAM) | ||
| JP7154243B2 (ja) | 潰瘍を処置するための方法および組成物 | |
| JP6649895B2 (ja) | 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法 | |
| Kuter | The biology of thrombopoietin and thrombopoietin receptor agonists | |
| TWI758237B (zh) | 治療骨髓發育不良症候群及含鐵胚血球性貧血（ｓｉｄｅｒｏｂｌａｓｔｉｃ ａｎｅｍｉａｓ）之方法 | |
| JP6542433B2 (ja) | 単独でのまたは化学療法と組み合わされた変異アクチビン受容体ポリペプチド、およびその使用 | |
| ES2984470T3 (es) | Composiciones para su uso en el tratamiento de la mielofibrosis | |
| JP2021054839A (ja) | シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用 | |
| JP2012509687A (ja) | アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用 | |
| JP2011530599A5 (OSRAM) | ||
| JP2017516756A5 (OSRAM) | ||
| JP2003534384A (ja) | 神経保護性ペプチド | |
| US9545433B2 (en) | Myonectin (CTRP15), compositions comprising same, and methods of use | |
| US20070149439A1 (en) | Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo | |
| JP2019531070A (ja) | ツイスティッド・ガストルレーション・ポリペプチドおよびその用途 | |
| US20060286117A1 (en) | Neuronally expressed stem cell factor modulates angiogenesis and neural stem cell migration to areas of brain injury | |
| KR20250029015A (ko) | 다발성 골수종의 치료를 위한, 다른 제제와 조합된 이사툭시맙의 용도 | |
| JP2022524814A (ja) | 抗ｌｉｎｇｏ－１抗体を含む医薬組成物 | |
| HK40008525A (en) | Methods and compositions for treating myelofibrosis | |
| HK1234417B (en) | Methods for increasing red blood cell levels and treating sickle-cell disease | |
| HK1236427A1 (en) | Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia | |
| HK1236427B (en) | Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia |